DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

MRK·Merck & Co., Inc.

$.
-. (-.%)
High
$123.30
Open
$122.90
Market Cap
302.33B
52W High
$125.14
Low
$121.52
P. Close
$122.41
P/E
33.84
52W Low
$75.40
Fwd P/E
51.05
Mean Target
-
Technical Score (1D)
64
BUY
News Sentiment
61
BULLISH
Merck (MRK) is collaborating with Adcendo to evaluate its tissue factor-targeting ADC, ADCE-T02, in combination with Keytruda in a Phase 1b study for advanced solid tumors. This partnership aims to explore the synergistic potential of combining antibody-drug conjugates with anti-PD-1 therapies, potentially leading to enhanced anti-tumor activity through complementary mechanisms. Separately, the Committee for Medicinal Products for Human Use (CHMP) has recommended a Keytruda combination therapy for bladder cancer, offering new treatment avenues and signaling potential future revenue growth for the oncology drug. These developments come as the company faces looming patent expirations for Keytruda in 2028 in the U.S. and 2030 in Europe, which have impacted investor sentiment given its significant revenue contribution. Investors will be watching for further data from the Adcendo collaboration and the regulatory outcome of the CHMP recommendation for the bladder cancer indication.
Earnings Summary
Merck & Co., Inc. is a global healthcare leader focused on discovering, developing, and delivering innovative medicines and vaccines, operating within the Drug Manufacturers - General industry. The company's business centers on human health pharmaceuticals, with a diverse portfolio spanning oncology, vaccines, and diabetes, complemented by a significant presence in animal health. Strategic collaborations bolster its research and development pipeline. In its most recent reported quarters, Merck demonstrated a mixed performance. For Q1 2026, the company reported an actual EPS of -1.28 against an estimate of 2.09, a significant miss, while revenue was 16.286 billion against an estimate of 16.18 billion, a slight beat. This followed Q4 2025 where actual EPS was 2.04, beating the estimate of 2.03, and revenue was 16.4 billion, beating the estimate of 16.35 billion. The trend shows a deceleration in EPS performance from Q4 2025 to Q1 2026, with a notable miss in the latter, while revenue has shown a slight beat in the most recent periods. Historically, Merck has shown a strong revenue growth trajectory, with Q3 2025 revenue reaching 17.276 billion, a substantial increase. The company has a pattern of beating revenue estimates when provided, but EPS performance has been more volatile, with a significant miss in Q1 2026. Recent news highlights positive developments in Merck's oncology pipeline, including positive opinions from the European CHMP for KEYTRUDA and Padcev combination therapy for bladder cancer and strong Phase 3 results for sacituzumab tirumotecan in advanced endometrial cancer. An investigational drug also showed a 65% reduction in lung cancer progression risk. These advancements underscore strategic focus and pipeline growth, though projected challenges for Gardasil vaccine sales in 2026 due to weak demand from China present a headwind. Investors will be watching for final EU approval timelines for the bladder cancer combination, further data on endometrial cancer treatments, and the impact of these oncology successes against potential vaccine segment headwinds in upcoming quarters.

EPS

EstBeatMiss
$-1.86$-0.60$0.65$1.90$3.16Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.15 - -
Q1'26$2.09$-1.28-161.2%
Q4'25$2.03$2.04+0.5%
Q3'25$2.35$2.58+9.9%
Q2'25$2.03$2.13+5.0%
Q1'25$2.14$2.22+4.0%

Revenue

EstBeatMiss
$15.3B$15.8B$16.4B$17.0B$17.5BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$16.5B - -
Q1'26$16.2B$16.3B+0.7%
Q4'25$16.3B$16.4B+0.3%
Q3'25 - $17.3B -
Q2'25 - $15.8B -
Q1'25 - $15.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MRK Stock Snapshot

MRK is currently trading at $121.65, giving Merck & Co., Inc. a market cap of 302.33B and a P/E ratio of 33.8. Today's range spans $121.52–$123.30, with shares opening at $122.90 and moving down $0.76 (0.6%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 61/100.

Over the past year MRK has traded between $75.40 and $125.14 - the current price is +61.3% off the 52-week low and -2.8% from the high.

MRK is in a holding pattern - 64/100 technical score, HOLD signal, price at $121.65 (near 52-week highs), sentiment bullish at 61/100. (P/E: 33.8) At 302.33B in Healthcare market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $75.40–$125.14. The next catalyst, not the current setup, determines the exit from this range.

Portfolio construction in Healthcare often uses large-cap names like MRK as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 64/100 (HOLD) at $121.65 (near 52-week highs) and bullish sentiment (61/100) frame the position as a catalyst play within the $75.40–$125.14 annual range rather than a directional bet.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…